A-Alpha Bio Inc.
Seattle, WA
- UEI
- HCTNBH41FKL1
- CAGE
- 7ZQ69
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2101 4th Ave #500, Seattle, WA 98121, USA
- Website
- aalphabio.com
- Founded
- 2017
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Dotquant LLC | Shoreline, WA | — |
| Pumpkinseed Technologies Inc. | Palo Alto, CA | 541713 Research and Development in Nanotechnology |
| Adeptrix Corp | Boston, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Invvax, Inc. | Cypress, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| BPS Bioscience Inc. | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
A-Alpha Bio Inc. is a biotechnology company that specializes in measuring protein-protein interactions using synthetic biology and machine learning techniques. They aim to rapidly and quantitatively measure the affinities of millions of protein-protein interactions. A-Alpha Bio Inc. has been registered in the System for Award Management (SAM.gov) since October 28, 2017, and its registration is set to expire on September 19, 2024. It is a for-profit corporate entity.
Through federal contract awards, A-Alpha Bio Inc. has provided operational services as a subcontractor to the Massachusetts Institute of Technology (MIT). The specific details of these services are not provided in the information given, but it is likely related to A-Alpha Bio Inc.'s expertise in biotechnology and protein-protein interaction measurements.
Through federal grant awards, A-Alpha Bio Inc. has received funding from the National Science Foundation (NSF) for two projects. The first grant, awarded on September 1, 2020, and completed on August 31, 2021, was a Small Business Innovation Research (SBIR) Phase I project titled "DEVELOPING A RAPID ANTIBODY GENERATION PLATFORM FOR EMERGING COVID-19 VARIANTS." This project aimed to develop a platform for rapidly generating antibodies against emerging COVID-19 variants. The second grant, awarded on May 1, 2020, and set to be completed on December 31, 2024, is an SBIR Phase II project titled "DEVELOPING A PLATFORM FOR MULTIPLEXED DRUG PROFILING USING YEAST SYNTHETIC AGGLUTINATION." This project focuses on developing a platform for multiplexed drug profiling using yeast synthetic agglutination, which could potentially be used for drug discovery and development purposes.
Quick answers
Is A-Alpha Bio Inc. registered in SAM.gov?
Yes. A-Alpha Bio Inc.'s SAM.gov registration is active through March 10, 2027.
What is A-Alpha Bio Inc.'s most recent federal award?
A-Alpha Bio Inc.'s most recent federal grant award is Sbir phase i: developing a rapid antibody generation platform for emerging covid-19 variants (2033772), from Division of Industrial Innovation, on September 1, 2020.
On GovTribe
See A-Alpha Bio Inc.'s full federal record
- IDV awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors